Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

Placenta Transfer and Toxicokinetics of Valproic Acid in Pregnant Cynomolgus Monkeys

  • Received : 2010.11.02
  • Accepted : 2010.11.14
  • Published : 2010.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Placenta transfer study in non-human primate (NHP) is one of the crucial components in the assessment of developmental toxicity because of the similarity between NHP and humans. To establish the method to determine placenta transfer in non-human primate, toxicokinetics of valproic acid (VPA), a drug used to treat epilepsy in pregnant women, were determined in pregnant cynomolgus monkeys. After mating, pregnancy-proven females were daily administered with VPA at dose levels of 0, 20, 60 and 180 mg/kg by oral route during the organogenesis period from gestation day (GD) 20 to 50. Concentrations of VPA and its metabolite, 4-ene-VPA, in maternal plasma on GDs 20 and 50, and concentrations of VPA and 4-ene-VPA in placenta, amniotic fluid and fetus on GD 50 were analyzed using LC/MS/MS. Following single oral administration of VPA to pregnant monkeys, concentrations of VPA and 4-ene-VPA were generally quantifiable in the plasma from all treatment groups up to 4-24 hours post-dose, demonstrating that VPA was absorbed and the monkeys were systemically exposed to VPA and 4-ene-VPA. After repeated administration of VPA to the monkeys, VPA was detected in amniotic fluid, placenta and fetus from all treatment groups, demonstrating that VPA was transferred via placenta and the fetus was exposed to VPA, and the exposures were increased with increasing dose. Concentrations of 4-ene-VPA in amniotic fluid and fetus were below the limit of quantification, but small amount of 4-ene-VPA was detected in placenta. In conclusion, pregnant monkeys were exposed to VPA and 4-ene-VPA after oral administration of VPA at dose levels of 20, 60 and 180 mg/kg during the organogenesis period. VPA was transferred via placenta and the fetus was exposed to VPA with dose-dependent exposure. The metabolite, 4-ene VPA, was not detected in both amniotic fluid and fetus, but small amount of 4-ene-VPA was detected in placenta. These results demonstrated that proper procedures to investigate placenta transfer in NHP, such as mating and diagnosis of pregnancy via examining gestational sac with ultrasonography, collection of amniotic fluid, placenta and fetus after Caesarean section followed by adequate bioanalysis and toxicokinetic analysis, were established in this study using cynomolugus monkeys.

Keywords

References

  1. Alsdorf, R. and Wyszynski, D.F. (2005). Teratogenicity of sodium valproate. Expert Opin Drug Saf., 4, 345-353. https://doi.org/10.1517/14740338.4.2.345
  2. Binkerd, P.E., Rowland, J.M., Nau, H. and Hendrickx, A.G. (1988). Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl. Toxicol., 11, 485-493. https://doi.org/10.1016/0272-0590(88)90112-1
  3. Dickinson, R.G., Kaufman, S.N., Lynn, R.K., Cook, M.J., Novy, M.J. and Gerber, N. (1979). Materno-fetal pharmacokinetics and fetal distribution of valproic acid in the monkey. Proc. West. Pharmacol. Soc., 22, 57-61.
  4. Dickinson, R.G., Lawyer, C.H., Kaufman, S.N., Lynn, R.K., Gerber, N., Novy, M.J. and Cook, M.J. (1980). Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. Pediatr Pharmacol., 1, 71-83.
  5. Emmanouil-Nikoloussi, E.N., Foroglou, N.G., Kerameos-Foroglou, C.H. and Thliveris, J.A. (2004). Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study. Morphologie., 88, 41-45. https://doi.org/10.1016/S1286-0115(04)97999-4
  6. Hauck, R.S. and Nau, H. (1989). Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Tox. Lett., 49, 41-48. https://doi.org/10.1016/0378-4274(89)90099-4
  7. Hendrickx, A.G., Nau, H., Binkerd, P., Rowland, J.M., Rowland, J.R., Cukierski, M.J. and Cukierski, M.A. (1988) Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology, 38, 329-345. https://doi.org/10.1002/tera.1420380405
  8. Mast, T.J., Cukierski, M.A., Nau, H. and Hendrickx, A.G. (1986). Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology, 39, 111-119. https://doi.org/10.1016/0300-483X(86)90129-0
  9. Menegola, E., Broccia, M.L., Nau, H., Prati, M., Ricolfi, R. and Giavini, E. (1996). Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen., 16, 97-108. https://doi.org/10.1002/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.0.CO;2-A
  10. Nau, H. (1986). Species differences in pharmacokinetics and drug teratogenesis. Environ. Health Perspect., 70, 113-129. https://doi.org/10.2307/3430348
  11. Nau, H., Hauck, R.S. and Ehlers, K. (1991). Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol., 69, 310-21. https://doi.org/10.1111/j.1600-0773.1991.tb01303.x
  12. Ohdo, S., Ogawa, N., Nakano, S. and Higuchi, S. (1996). Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J. Pharmacol. Exp. Ther., 278, 74-81.
  13. Ornoy, A. (2006). Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol., 22, 214-226. https://doi.org/10.1016/j.reprotox.2006.03.014
  14. Ornoy, A. (2009). Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol., 28, 1-10. https://doi.org/10.1016/j.reprotox.2009.02.014
  15. Rettenmeier, A.W., Gordon, W.P., Prickett, K.S., Levy, R.H. and Baillie, T.A. (1986a). Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug Metab Dispos., 14, 454-64.
  16. Rettenmeier, A.W., Gordon, W.P., Prickett, K.S., Levy, R.H., Lockard, J.S., Thummel, K.E. and Baillie, T.A. (1986b). Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. Drug Metab Dispos., 14, 443-453.
  17. Rosenberg, G. (2007). The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell. Mol. Life Sci., 64, 2090-2103. https://doi.org/10.1007/s00018-007-7079-x
  18. Semmes, R.L. and Shen, D.D. (1990). Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins. Pharm. Res., 5, 461-467.
  19. Tong, V., Teng, X.W., Chang, T.K and Abbott, F.S. (2005). Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol. Sci., 86, 427-435. https://doi.org/10.1093/toxsci/kfi184
  20. Vorhees, C.V. (1987). Teratogenicity and developmental toxicity of valproic acid in rats. Teratology, 35, 195-202. https://doi.org/10.1002/tera.1420350205
  21. Vorhees, C.V., Acuff-Smith, K.D., Weisenburger, W.P., Minck, D.R., Berry, J.S., Setchell, K.D. and Nau, H. (1991). Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats. Teratology, 43, 583-590. https://doi.org/10.1002/tera.1420430613
  22. Wide, K., Winbladh, B. and Källén, B. (2004). Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr., 93, 174-176. https://doi.org/10.1080/08035250310021118

Cited by

  1. Milk Transfer and Toxicokinetics of Valproic Acid in Lactating Cynomolgus Monkeys vol.29, pp.1, 2013, https://doi.org/10.5487/TR.2013.29.1.053
  2. The protective effect of polyunsaturated fatty acid intake during pregnancy against embryotoxicity of sodium valproate in mice vol.9, pp.5, 2018, https://doi.org/10.1039/C7FO01604B